Skip to main content
. 2020 Dec 10;9(3):257–268. doi: 10.1093/gastro/goaa060

Figure 1.

Figure 1.

The expression of PACER in CRC-tissue samples. (A) The expression of PACER in 41 normal-tissue samples and 272 CRC-tissue samples from the TCGA database (P < 0.001). (B) Kaplan–Meier analyses of overall survival (OS) for PACER expression in the TCGA database (P = 0.007). (C) The expression of PACER in 46 pairs of normal-tissue and cancer-tissue samples was detected by RT-qPCR assays (P < 0.001). (D) The overall survival (OS) for PACER expression in CRC samples (P = 0.020). (E) Increased PACER expression in tumor tissue was associated with TNM stages based on data from the TCGA database (P = 0.007). (F) The average expression of PACER increased with TNM stages in 46 patients (P = 0.019). PACER, p50-associated cyclooxygenase-2 extragenic RNA; CRC, colorectal cancer.